Wakamoto Pharmaceutical Co., Ltd. operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Wakamoto Pharmaceutical Co., Ltd. with three other
companies in this sector in Japan:
I'rom Group Co Ltd
sales of 8.62 billion Japanese Yen [US$75.78 million]
of which 73%
was Smo Business),
Koei Chemical Company, Limited
(18.14 billion Japanese Yen [US$159.49 million]
Biofermin Pharmaceutical Company Limited
(10.88 billion Japanese Yen [US$95.61 million]
of which 62%
was New BioferminS).
Wakamoto Pharmaceutical Co., Ltd. reported sales of ¥10.90 billion (US$95.82 million)
March of 2018.
a very small
increase of 0.7%
versus 2017, when the company's sales were ¥10.83 billion.
Despite this increase, sales are still
below the level achieved in 2016, when Wakamoto Pharmaceutical Co., Ltd.
reported sales of ¥11.18 billion.
The sales level in 2018 was fairly close to the level five years ago: in 2013, Wakamoto Pharmaceutical Co., Ltd. had sales
of ¥9.93 billion.
Sales of Drugs saw an increase
that was more than double the company's growth rate: sales were up
7.3% in 2018, from
¥2.82 billion to ¥3.02 billion.
Not all segments of Wakamoto Pharmaceutical Co., Ltd. experienced an increase in sales in 2018:
sales of Medical Pharmaceutical Products fell 1.9% to ¥5.58 billion.
Wakamoto Pharmaceutical Co., Ltd. also experienced decreases in sales in
Specified Sales Bussiness (down 1.3% to ¥2.11 billion)